Targeting HER2-low in metastatic breast cancer: an evolving treatment paradigm.

"CY had no conflicts to disclose. CB-M reports serving in a consultancy or advisory role and receiving honoraria from Amgen, AstraZeneca, BMS, Eli Lilly, Gilead, Knight Therapeutics, Mylan, Novartis, Pfizer, Roche, Seagen, and Taiho and has received research funding from Eli Lilly and AstraZeneca. AAJ has served in a consultancy or advisory role and has received honoraria from AstraZeneca, BMS, Eli Lilly, Gilead, Knight Therapeutics, Mylan, Novartis, Pfizer, Roche, and Teva. SS reports participating in advisory boards and/or receiving speaker fees from AstraZeneca, Gilead, Roche, Novartis, and Merck. SM has been a scientific advisor for AstraZeneca, Daiichi Sankyo, Eli Lilly, Genentech, Gilead, GlaxoSmithKline, Macrogenics, Puma Biotechnology, Seagen, and Zymeworks. SM also reports attending speaking engagements for AstraZeneca, Daiichi Sankyo, Genentech, Novartis, and Seagen and being a primary investigator on trials for AstraZeneca, Daiichi Sankyo, Genentech, and Seagen. CS has served in a consultancy or advisory role and received honoraria from Eli Lilly, Mylan, Pfizer, and Roche, and CS has received research funding from AstraZeneca Global, Knight Therapeutics, Roche, Pfizer, and Viatris. J-WH reports serving in a consultancy or advisory role and receiving honoraria from AstraZeneca, Eli Lilly, Knight Therapeutics, Mylan, Novartis, Pfizer, Roche, and Seagen. J-WH also reports having speaking arrangements with Gilead and receiving research grant support from AstraZeneca, Novartis, and Pfizer."

"Funding: The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: Development and publication of this work were supported by AstraZeneca Canada."